Voices
Daniel Auclair, Myeloproliferative Syndromes
Daniel Auclair/X

Daniel Auclair: Myeloproliferative Syndromes and Neoplasms – Beyond JAK Inhibitors at ASH25

Daniel Auclair, President of Hematocure, shared a post on X:

“ASH25: Myeloproliferative syndromes and neoplasms: beyond JAK inhibitors

Mutant calreticulin-targeting:

INCA033989

Dr. John Mascarenhas

ADC

TCEs

Activin receptor targeting:

Elritercep (KER-050, TAK-226)

zilurgisertib (INCB000928)

IL-1b blocking

Canakinumab

BRD inhibitor INCB057643

Menin inhibition for MPNs.”

More posts featuring Daniel Auclair.

ASH25 cancer Daniel Auclair myeloproliferative syndromes OncoDaily Oncology